PTU - Polskie Towarzystwo Urologiczne
list of articles:

THERAPY OF LOCALISED PROSTATE CANCER - Challenge to define personal position
Article published in Urologia Polska 1995/48/1.

authors

Andrzej Borkowski
Klinika i Katedra Urologii Akademii Medycznej w Warszawie

summary

Rationale (based on results of prospective, multicenter clinical trials) for radical treatment
modalities currently applied in early stages of prostate cancer has not yet been elaborated. No
markers facilitating treatment decision in every individual patient are available so far. Thus
extreme therapeutic managements may be observed: from an aggresive attitude, proposing
radical treatment in every case, to watchful waiting, offering follow up and hormonal
manipulation on time of progression.
An algorithm proposing potential decision is presented, depending on patient's age, serum
PSA level and results of systematic, spatially oriented, transrectal ultrasound guided core
biopsies of prostate.

references

  1. 1. Adolfsson J.a Carstensen J., Lowhagen T.: Defferred treatment in Clinically localised
  2. prostatic carcinoma. Br. J. Urol. 1992, 69, 183. ?2. Bagshaw M.A., Cox R.X., Ranback J.E.:
  3. Radiation therapy for localised prostate cancer. Justification by long-term follow up. Urol. Clin.
  4. North. Am. 1990, 17, 787. ? 3. Cantrell B.B., De Klerk D.P., Eggleston J.C., Boinott J.K.,
  5. Walsh P.C.: Pathological factors that influence prognosis in stage A prostatic cancer: The
  6. influence of extent versus grade. J. Urol. 1981, 125, 516. ? 4. Chisholm G.D., Rana A.: Is the
  7. outcome of conservative management for localised prostate cancer acceptable? An overview.
  8. Eur. Urol. 1993, 24 (suppl 2), 64. ? 5. Chybowski F., Larson Keller J., Bergstralh E., Oesterling
  9. J.\ Predicting radionucleide bone scan findings in patients with newly diagnosed, untreated
  10. prostate cancer: prostate specific antigen is superior to other clinical parameters. J. Urol. 1991,
  11. 145, 313. ? 6. Cooner W.H.: Editorial: prostate cancer. J. Urol. 1994,151, 103. ? 7. Dalkin B.,
  12. Ahman F., Southtoick P., Bottacini M.\ Derrivation of normal prostate specific antigen (PSA) by
  13. age. AUA 88 th Annual Meeting. 1993, J. Urol. 1993, 149,413A. ? 8. DanellaJ.F., de Kernion
  14. J., Smith R.B., Steckel J.\ The contemporary incidence of lymph node metastases in prostate
  15. cancer: implications for laparoscopic lymph node dossection. J. Urol. 1993, 149, 1488. ?
  16. 9. Epstein JJ., Paul G., Eggleston J.C., Walsh P.C.: Prognosis of unterated stage Al prostatic
  17. carcinoma: A study of 94 cases with extended follow-up. J. Urol. 1986,136, 837. ? 10. Epstein
  18. J.I., Walsh P.C., Brendler Ch.B.: Radical prostatectomy for impalpable prostate cancer: the
  19. Johns Hopkins experience with tumors found on transurethral resection (stages Tl a i Tlb) on
  20. needle biopsy (stage Tle). J. Urol. 1994, 152, 1721.
  21. 11. Flanigan R.C., Catalona W.J., Richie J.P., Ahmann F.R., Hudson M.A., Scardino
  22. P.T., de Kernion J.B., Ratlif T.L., Kavoussi L.R., Dalkin B.L., Waters W.B., McFarlane M.T.,
  23. Soutwick P.C.: Accuracy of digital rectal examination and transrectal ultrasonography in
  24. localizing prostate cancer. J. Urol. 1994, 152, 1506. ? 12. Freiha F.S., Bagshaw M.A.:
  25. Carcinoma of the prostate: Results of postirradiation biopsy. Prostate 1984, 5, 19. ? 13. Gerber
  26. G.j Rukstalis D., Chodak G.: Correlation of prostate specific antigen and tumor grade with nodal
  27. status in man with Clinically localised prostate cancer. AUA 88th Annual Meeting. J. Urol.
  28. 1993, 149, 448A. ? 14. Heaney J.A., Chang H.C., Daly J.J., Prout G.R.Jr.: Prognosis of
  29. Clinically undiagnosed prostatic carcinoma and the influence of endocrine therapy. J. Urol.
  30. 1977, 118, 283. ? 15. Johansson J.E., Andersson S.O., Krusemo U.B., Adami H.O., Bergstrom
  31. R.,Kraaz W.: Natural history of localised prostatic cancer. Lancet 1989,1,799. ? 16. Johanson
  32. J.E., Adami H.O., Anderson S.O., Bergstrom R., Holmberg L., Krusemo U.B.: High 10-year
  33. survival rate in patients with early, untreated prostatic cancer. JAMA 1993, 267, 2191. ? 17.
  34. Mclntire T.L., Murphy W.M., CoonJ.S.: The Prognostic value of DNA ploidy combined with
  35. histologic substaging for incidental carcinoma of the prostate gland. Am. J. Clin. Pathol. 1988,
  36. 89, 370. ? 18. Partin A.W., Lee B.R., Carmichael M., Walsh P.C., Epstein J.I.: Radical prostatectomy for high grade disease: a reevaluation 1994. J. Urol. 1994, 151, 1583. ? 19.
  37. Rastry V., Boccon-Gibod L.A., Billebaud T., Dauge M.C, Haab F., Delmas V., Boccon-Gibod
  38. L.M.: Systematic random biopsies accurately predict extracapsular extension of prostate cancer
  39. md persistant/recurent detectable PSA after radical prostatecomy. Abstract Book of XI
  40. Congress EUA. Berlin 1994, abstr. 371. ? 20. Rukstalis D.B., Gerber G.S., Yogelzang N.J.,
  41. HarafD.J., Straus F.H., Chodak G.W.: Laparoscopic pelvic lymph node dissection: a review of
  42. 103 consecutive cases. J. Urol. 1994, 151, 670.
  43. 21. Scardino PT.: Early detection of prostate cancer. Urol. Clin. North. Am. 1989, 16,
  44. 635. ? 22. Seideman H., Mushinski M.H., Gelb S.K., Siherberg E.: Probabilities of eventually
  45. dercloping or dying of cancer ? United States. 1985, 35, 36. ? 23. Schroder F.H.: The limits of
  46. surgery in the cure of prostatic carcinoma E.B.U. European Update series. 1992 Vo. 1, Nr 3.
  47. ? 24. Stamey T.A., McNeal J.E., Freiha F.S., Redwine E.: Morphometric and clinical studies oo 68 consecutive radical prostatectomies. J. Urol. 1988,139,1235. ?25. Wu T.T., Chen K.K. Hmang J-K., Lee Y-H., Chen M-T., Chang L.S.: Prediction of lymphatic spreading in
  48. prosanc cancer by prostate specific antigen and Gleason score. Eur. Urol. 1994, 26, 202.